Metabolically healthy obesity

Last updated

Metabolically healthy obesity (MHO) is a disputed [1] medical condition characterized by obesity which does not produce metabolic complications. [2]

Contents

Characteristics

No universally accepted criteria exist to define putative MHO, [2] but definitions generally require the patient to be obese and to lack metabolic abnormalities such as dyslipidemia, impaired glucose tolerance, [1] or metabolic syndrome. [3]

MHO individuals display less visceral adipose tissue, smaller adipocytes, and a reduced inflammatory profile relative to metabolically unhealthy obese individuals. [3] [4] [5] As a result, it has been argued that cardiometabolic risk might not improve significantly as a result of weight loss interventions. [6]

Epidemiology

Prevalence estimates of MHO have varied from 6 to 75 percent, [7] and it has been argued that between 10 and 25 percent of obese individuals are metabolically healthy. [8] One study found that 47.9% of obese people had MHO, while another found that 11% did. [3] It seems to be more prevalent in women than men, and its prevalence decreases with age. [9] [10]

Outcomes

Some research suggests that metabolically healthy obese individuals are at an increased risk of several adverse outcomes when compared to individuals of a normal weight, including type 2 diabetes, [11] depressive symptoms, [12] and cardiovascular events. [13] [14] Other research also suggests that although MHO individuals display a favorable metabolic profile, this does not necessarily translate into a decrease in mortality. [15] Research to date has produced conflicting results with respect to cardiovascular disease and mortality. [16] MHO individuals are at a higher risk of cardiovascular disease compared to metabolically healthy non-obese individuals, but they are also at a lower risk thereof than individuals who are both unhealthy and obese. [17] [18] A 2016 meta-analysis found that MHO individuals were not at an increased risk of all-cause mortality (but were at an increased risk of cardiovascular events). [19] The relatively low risk of cardiovascular disease among people with MHO relative to metabolically unhealthy obese people has been attributed to differences in white adipose tissue function between the two groups. [20]

See also

Related Research Articles

<span class="mw-page-title-main">Coronary artery disease</span> Reduction of blood flow to the heart

Coronary artery disease (CAD), also called coronary heart disease (CHD), ischemic heart disease (IHD), myocardial ischemia, or simply heart disease, involves the reduction of blood flow to the cardiac muscle due to build-up of atherosclerotic plaque in the arteries of the heart. It is the most common of the cardiovascular diseases. Types include stable angina, unstable angina, and myocardial infarction.

<span class="mw-page-title-main">Metabolic syndrome</span> Medical condition

Metabolic syndrome is a clustering of at least three of the following five medical conditions: abdominal obesity, high blood pressure, high blood sugar, high serum triglycerides, and low serum high-density lipoprotein (HDL).

<span class="mw-page-title-main">Abdominal obesity</span> Excess fat around the stomach and abdomen

Abdominal obesity, also known as central obesity and truncal obesity, is the human condition of an excessive concentration of visceral fat around the stomach and abdomen to such an extent that it is likely to harm its bearer's health. Abdominal obesity has been strongly linked to cardiovascular disease, Alzheimer's disease, and other metabolic and vascular diseases.

<span class="mw-page-title-main">Obesity</span> Medical condition in which excess body fat harms health

Obesity is a medical condition, sometimes considered a disease, in which excess body fat has accumulated to such an extent that it can potentially have negative effects on health. People are classified as obese when their body mass index (BMI)—a person's weight divided by the square of the person's height—is over 30 kg/m2; the range 25–30 kg/m2 is defined as overweight. Some East Asian countries use lower values to calculate obesity. Obesity is a major cause of disability and is correlated with various diseases and conditions, particularly cardiovascular diseases, type 2 diabetes, obstructive sleep apnea, certain types of cancer, and osteoarthritis.

<span class="mw-page-title-main">Type 2 diabetes</span> Type of diabetes mellitus with high blood sugar and insulin resistance

Type 2 diabetes (T2D), formerly known as adult-onset diabetes, is a form of diabetes mellitus that is characterized by high blood sugar, insulin resistance, and relative lack of insulin. Common symptoms include increased thirst, frequent urination, fatigue and unexplained weight loss. Symptoms may also include increased hunger, having a sensation of pins and needles, and sores (wounds) that do not heal. Often symptoms come on slowly. Long-term complications from high blood sugar include heart disease, strokes, diabetic retinopathy which can result in blindness, kidney failure, and poor blood flow in the limbs which may lead to amputations. The sudden onset of hyperosmolar hyperglycemic state may occur; however, ketoacidosis is uncommon.

<span class="mw-page-title-main">Mediterranean diet</span> Diet inspired by the Mediterranean region

The Mediterranean diet is a diet inspired by the eating habits and traditional food typical of southern Spain, southern Italy, and Crete, and formulated in the early 1960s. It is distinct from Mediterranean cuisine, which covers the actual cuisines of the Mediterranean countries, and from the Atlantic diet of northwestern Spain and Portugal. While inspired by a specific time and place, the "Mediterranean diet" was later refined based on the results of multiple scientific studies.

<span class="mw-page-title-main">Cardiovascular disease</span> Class of diseases that involve the heart or blood vessels

Cardiovascular disease (CVD) is any disease involving the heart or blood vessels. CVDs constitute a class of diseases that includes: coronary artery diseases, heart failure, hypertensive heart disease, rheumatic heart disease, cardiomyopathy, arrhythmia, congenital heart disease, valvular heart disease, carditis, aortic aneurysms, peripheral artery disease, thromboembolic disease, and venous thrombosis.

<span class="mw-page-title-main">Adiponectin</span> Mammalian protein found in Homo sapiens

Adiponectin is a protein hormone and adipokine, which is involved in regulating glucose levels and fatty acid breakdown. In humans, it is encoded by the ADIPOQ gene and is produced primarily in adipose tissue, but also in muscle and even in the brain.

Bariatrics is the branch of medicine that deals with the causes, prevention, and treatment of obesity.

<span class="mw-page-title-main">Healthy diet</span> Type of diet

A healthy diet is a diet that maintains or improves overall health. A healthy diet provides the body with essential nutrition: fluid, macronutrients such as protein, micronutrients such as vitamins, and adequate fibre and food energy.

<span class="mw-page-title-main">Metabolic dysfunction–associated steatotic liver disease</span> Excessive fat buildup in the liver with other metabolic disease

Metabolic dysfunction–associated steatotic liver disease (MASLD) is the name adopted in 2023 for the condition previously known as non-alcoholic fatty liver disease (NAFLD). This condition is diagnosed when there is excessive fat build-up in the liver, and at least one metabolic risk factor. When there is also moderate alcohol use, the term MetALD is used, and these are differentiated from alcoholic liver disease (ALD) when this is the sole cause of steatotic liver disease. The terms non-alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis have been used to describe different severities, the latter indicating the presence of further liver inflammation. NAFL is less dangerous than NASH and usually does not progress to it, but this progression may eventually lead to complications, such as cirrhosis, liver cancer, liver failure, and cardiovascular disease.

Bariatric surgery is a medical term for surgical procedures used to manage obesity and obesity-related conditions. Long term weight loss with bariatric surgery may be achieved through alteration of gut hormones, physical reduction of stomach size, reduction of nutrient absorption, or a combination of these. Standard of care procedures include Roux en-Y bypass, sleeve gastrectomy, and biliopancreatic diversion with duodenal switch, from which weight loss is largely achieved by altering gut hormone levels responsible for hunger and satiety, leading to a new hormonal weight set point.

The obesity paradox is the finding in some studies of a lower mortality rate for overweight or obese people within certain subpopulations. The paradox has been observed in people with cardiovascular disease and cancer. Explanations for the paradox range from excess weight being protective to the statistical association being caused by methodological flaws such as confounding, detection bias, reverse causality, or selection bias.

<span class="mw-page-title-main">Preventable causes of death</span> Causes of death that could have been avoided

Preventable causes of death are causes of death related to risk factors which could have been avoided. The World Health Organization has traditionally classified death according to the primary type of disease or injury. However, causes of death may also be classified in terms of preventable risk factors—such as smoking, unhealthy diet, sexual behavior, and reckless driving—which contribute to a number of different diseases. Such risk factors are usually not recorded directly on death certificates, although they are acknowledged in medical reports.

A person's waist-to-height ratio (WHtR), occasionally written WtHR or called waist-to-stature ratio (WSR), is defined as their waist circumference divided by their height, both measured in the same units. It is used as a predictor of obesity-related cardiovascular disease. The WHtR is a measure of the distribution of body fat. Higher values of WHtR indicate higher risk of obesity-related cardiovascular diseases; it is correlated with abdominal obesity.

Testosterone and the cardiovascular system are the effects that the male hormone testosterone has on the cardiovascular system.

Normal weight obesity is the condition of having normal body weight, but with a high body fat percentage, leading to some of the same health risks as obesity.

Major adverse cardiovascular events is a composite endpoint frequently used in cardiovascular research. Despite widespread use of the term in clinical trials, the definitions of MACE can differ, which makes comparison of similar studies difficult.

The benefits of physical activity range widely. Most types of physical activity improve health and well-being.

References

  1. 1 2 Puri, Rishi (June 2014). "Is it Finally Time to Dispel the Concept of Metabolically-Healthy Obesity?". Journal of the American College of Cardiology. 63 (24): 2687–2688. doi: 10.1016/j.jacc.2014.03.043 . PMID   24794116.
  2. 1 2 Stefan, Norbert; Häring, Hans-Ulrich; Hu, Frank B; Schulze, Matthias B (October 2013). "Metabolically healthy obesity: epidemiology, mechanisms, and clinical implications". The Lancet Diabetes & Endocrinology. 1 (2): 152–162. doi:10.1016/S2213-8587(13)70062-7. PMID   24622321.
  3. 1 2 3 Denis, Gerald V.; Obin, Martin S. (February 2013). "'Metabolically healthy obesity': Origins and implications". Molecular Aspects of Medicine. 34 (1): 59–70. doi:10.1016/j.mam.2012.10.004. PMC   3583231 . PMID   23068072.
  4. ↑ Navarro, Estanislau; Funtikova, Anna N.; Fíto, Montserrat; Schröder, Helmut (November 2014). "Can Metabolically Healthy Obesity be explained by diet, genetics and inflammation?". Molecular Nutrition & Food Research. 59 (1): 75–93. doi:10.1002/mnfr.201400521. PMID   25418549.
  5. ↑ Muñoz-Garach, Araceli; Cornejo-Pareja, Isabel; Tinahones, Francisco J. (1 June 2016). "Does Metabolically Healthy Obesity Exist?". Nutrients. 8 (6): 320. doi: 10.3390/nu8060320 . ISSN   2072-6643. PMC   4924161 . PMID   27258304.
  6. ↑ Bluher, M. (10 July 2014). "MECHANISMS IN ENDOCRINOLOGY: Are metabolically healthy obese individuals really healthy?". European Journal of Endocrinology. 171 (6): R209–R219. doi: 10.1530/EJE-14-0540 . PMID   25012199.
  7. ↑ Rey-López, JP; de Rezende, LF; Pastor-Valero, M; Tess, BH (October 2014). "The prevalence of metabolically healthy obesity: a systematic review and critical evaluation of the definitions used". Obesity Reviews. 15 (10): 781–90. doi:10.1111/obr.12198. PMID   25040597. S2CID   825441.
  8. ↑ Blüher, Matthias (February 2010). "The distinction of metabolically 'healthy' from 'unhealthy' obese individuals". Current Opinion in Lipidology. 21 (1): 38–43. doi:10.1097/MOL.0b013e3283346ccc. PMID   19915462. S2CID   2054728.
  9. ↑ Blüher, Susann; Schwarz, Peter (September 2014). "Metabolically healthy obesity from childhood to adulthood — Does weight status alone matter?". Metabolism. 63 (9): 1084–1092. doi:10.1016/j.metabol.2014.06.009. PMID   25038727.
  10. ↑ van Vliet-Ostaptchouk, Jana V; Nuotio, Marja-Liisa; Slagter, Sandra N; Doiron, Dany; Fischer, Krista; Foco, Luisa; Gaye, Amadou; Gögele, Martin; Heier, Margit; Hiekkalinna, Tero; Joensuu, Anni; Newby, Christopher; Pang, Chao; Partinen, Eemil; Reischl, Eva; Schwienbacher, Christine; Tammesoo, Mari-Liis; Swertz, Morris A; Burton, Paul; Ferretti, Vincent; Fortier, Isabel; Giepmans, Lisette; Harris, Jennifer R; Hillege, Hans L; Holmen, Jostein; Jula, Antti; Kootstra-Ros, Jenny E; Kvaløy, Kirsti; Holmen, Turid; Männistö, Satu; Metspalu, Andres; Midthjell, Kristian; Murtagh, Madeleine J; Peters, Annette; Pramstaller, Peter P; Saaristo, Timo; Salomaa, Veikko; Stolk, Ronald P; Uusitupa, Matti; van der Harst, Pim; van der Klauw, Melanie M; Waldenberger, Melanie; Perola, Markus; Wolffenbuttel, Bruce HR (2014). "The prevalence of metabolic syndrome and metabolically healthy obesity in Europe: a collaborative analysis of ten large cohort studies". BMC Endocrine Disorders. 14 (1): 9. doi: 10.1186/1472-6823-14-9 . PMC   3923238 . PMID   24484869.
  11. ↑ Bell, JA; Kivimaki, M; Hamer, M (June 2014). "Metabolically healthy obesity and risk of incident type 2 diabetes: a meta-analysis of prospective cohort studies" (PDF). Obesity Reviews. 15 (6): 504–15. doi:10.1111/obr.12157. PMC   4309497 . PMID   24661566.
  12. ↑ Jokela, M; Hamer, M; Singh-Manoux, A; Batty, G D; Kivimäki, M (3 December 2013). "Association of metabolically healthy obesity with depressive symptoms: pooled analysis of eight studies". Molecular Psychiatry. 19 (8): 910–914. doi:10.1038/mp.2013.162. PMC   4921125 . PMID   24296976.
  13. ↑ Kramer, Caroline K.; Zinman, Bernard; Retnakaran, Ravi (3 December 2013). "Are Metabolically Healthy Overweight and Obesity Benign Conditions?". Annals of Internal Medicine. 159 (11): 758–69. doi:10.7326/0003-4819-159-11-201312030-00008. PMID   24297192. S2CID   9431877.
  14. ↑ Eckel, Nathalie; Meidtner, Karina; Kalle-Uhlmann, Tamara; Stefan, Norbert; Schulze, Matthias B (2016). "Metabolically healthy obesity and cardiovascular events: A systematic review and meta-analysis". European Journal of Preventive Cardiology. 23 (9): 956–966. doi:10.1177/2047487315623884. PMID   26701871. S2CID   6085134.
  15. ↑ Primeau, V; Coderre, L; Karelis, A D; Brochu, M; Lavoie, M-E; Messier, V; Sladek, R; Rabasa-Lhoret, R (26 October 2010). "Characterizing the profile of obese patients who are metabolically healthy". International Journal of Obesity. 35 (7): 971–981. doi:10.1038/ijo.2010.216. PMID   20975726.
  16. ↑ Phillips, Catherine M. (9 August 2013). "Metabolically healthy obesity: Definitions, determinants and clinical implications". Reviews in Endocrine and Metabolic Disorders. 14 (3): 219–227. doi:10.1007/s11154-013-9252-x. PMID   23928851. S2CID   489228.
  17. ↑ Roberson, Lara L; Aneni, Ehimen C; Maziak, Wasim; Agatston, Arthur; Feldman, Theodore; Rouseff, Maribeth; Tran, Thinh; Blaha, Michael J; Santos, Raul D; Sposito, Andrei; Al-Mallah, Mouaz H; Blankstein, Ron; Budoff, Matthew J; Nasir, Khurram (2014). "Beyond BMI: The "Metabolically healthy obese" phenotype & its association with clinical/subclinical cardiovascular disease and all-cause mortality -- a systematic review". BMC Public Health. 14 (1): 14. doi: 10.1186/1471-2458-14-14 . PMC   3890499 . PMID   24400816.
  18. ↑ Fan, Jingyao; Song, Yiqing; Chen, Yu; Hui, Rutai; Zhang, Weili (October 2013). "Combined effect of obesity and cardio-metabolic abnormality on the risk of cardiovascular disease: A meta-analysis of prospective cohort studies". International Journal of Cardiology. 168 (5): 4761–4768. doi:10.1016/j.ijcard.2013.07.230. PMID   23972953.
  19. ↑ Zheng, R; Zhou, D; Zhu, Y (28 April 2016). "The long-term prognosis of cardiovascular disease and all-cause mortality for metabolically healthy obesity: a systematic review and meta-analysis". Journal of Epidemiology and Community Health. 70 (10): 1024–1031. doi:10.1136/jech-2015-206948. PMID   27126492. S2CID   21145367.
  20. ↑ Badoud, F; Perreault, M; Zulyniak, MA; Mutch, DM (19 November 2014). "Molecular insights into the role of white adipose tissue in metabolically unhealthy normal weight and metabolically healthy obese individuals". FASEB Journal. 29 (3): 748–758. doi: 10.1096/fj.14-263913 . PMID   25411437.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.